Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. by Cox, H et al.
Acquired Drug Resistance in TB • CID 2007:44 (1 June) • 1421
MAJOR ARTICLE
Risk of Acquired Drug Resistance during Short-
Course Directly Observed Treatment of Tuberculosis
in an Area with High Levels of Drug Resistance
Helen S. Cox,
1,a Stefan Niemann,
2,a Gabit Ismailov,
3 Daribay Doshetov,
4 Juan Daniel Orozco,
3 Lucie Blok,
5,b
Sabine Ru ¨sch-Gerdes,
2 and Yared Kebede
5
1Australian International Health Institute, University of Melbourne, Australia;
2Forchungszentrum Borstel, National Reference Center for
Mycobacteria, Borstel, Germany;
3Me ´decins Sans Frontie `res and
4Ministry of Health, Nukus, Karakalpakstan, Uzbekistan; and
5Me ´decins Sans
Frontie `res, Amsterdam, The Netherlands
Background. Data on the performance of standardized short-course directly observed treatment (DOTS) of
tuberculosis (TB) in areas with high levels of drug resistance and on the potential impact of DOTS on ampliﬁcation
of resistance are limited. Therefore, we analyzed treatment results from a cross-sectional sample of patients with
TB enrolled in a DOTS program in an area with high levels of drug resistance in Uzbekistan and Turkmenistan
in Central Asia.
Methods. Sputum samples for testing for susceptibility to 5 ﬁrst-line drugs and for molecular typing were
obtained from patients starting treatment in 8 districts. Patients with sputum smear results positive for TB at the
end of the intensive phase of treatment and/or at 2 months into the continuation phase were tested again.
Results. Among 382 patients with diagnoses of TB, 62 did not respond well to treatment and were found to
be infected with an identical Mycobacterium tuberculosis strain when tested again; 19 of these patients had strains
that developed new or additional drug resistance. Ampliﬁcation occurred in only 1.2% of patients with initially
susceptible or monoresistant TB strains, but it occurred in 17% of those with polyresistant strains (but not
multidrug-resistant strains, deﬁned as strains with resistance to at least isoniazid and rifampicin) and in 7% of
those with multidrug-resistantstrainsat diagnosis.Overall,3.5%ofthepatientsnotinitiallyinfectedwithmultidrug-
resistant TB strains developed such strains during treatment. Ampliﬁcation of resistance, however, was found only
in polyresistant Beijing genotype strains.
Conclusions. High levels of ampliﬁcation of drug resistance demonstrated under well-established DOTS pro-
gram conditions reinforce the need for implementation of DOTS-Plus for multidrug-resistant TB in areas with
high levels of drug resistance. The strong association of Beijing genotype and ampliﬁcation in situations of
preexisting resistance is striking and may underlie the strong association between this genotype and drug resistance.
Resistance to tuberculosis (TB) drugs is emerging as a
threat to control of TB in many areas, particularly in
countries of the former Soviet Union [1]. High levels
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of multidrug-resistant (MDR) TB, deﬁned as TB with
resistance to at least isoniazid and rifampicin (the 2
most powerful TB drugs currently available), are con-
sistently demonstrated in surveys conducted in the re-
gion [1–4]. Despite this ﬁnding, access to drug suscep-
tibility testing and to appropriate second-line drug
therapy for MDR TB is limited [5, 6]. As a result, most
patients are treated with standard ﬁrst-line chemo-
therapy, such as that recommended by the short-course
directly observed treatment (DOTS) strategy [5, 6].Not
surprisingly, treatment of MDR TB with standardized
short-course chemotherapy results in substantially
poorer treatment outcomes than does treatment of
drug-susceptible TB strains [7]. In addition, standard-
ized treatment of patients infected with strains already1422 • CID 2007:44 (1 June) • Cox et al.
resistant to some ﬁrst-line drugs promotes the risk of the de-
velopment of additional drug resistance caused by inadvertent
inadequate therapy.
Resistance to TB drugs arises from inadequatechemotherapy
because of either inappropriate prescription, poor drug quality
or supply, or poor adherence to treatment [1].Theseconditions
can result in the effective exposure of bacilli to a single drug;
under these conditions, small numbers of spontaneously oc-
curring drug-resistant mutants have a selective advantage and,
therefore, multiply [8]. For this reason, it is well known that
a single drug should not be added to a failing regimen. A
regimen that includes drugs against which a strain has primary
drug resistance may have the same effect as single-drug therapy
in terms of the selection of resistant subpopulations. This effect
has been termed “ampliﬁcation” of drug resistance [9] and has
been demonstrated in several contexts [10–12].
To quantify the extent of acquired drug resistance during
DOTS chemotherapy in an area with a high level of initial drug
resistance, we assessed data from a drug resistance surveillance
study conducted in 2 regions of Central Asia: Karakalpakstan
in Uzbekistan and Dashoguz in Turkmenistan (rates of MDR
TB in 2001 were 27% in Karakalpakstan and 11% in Dashoguz)
(Appendix; online only).
METHODS
Study design. This study is an extension of a cross-sectional
drug resistance survey conducted in both Karakalpakstan and
Dashoguz. Patients were recruited as previously described [2].
Additional details are described in the Appendix (online only).
TB treatment and additional sampling. In addition to
sputum samples obtained at diagnosis and used for the drug
resistance survey, sputum samples wereobtainedwhenapatient
continued to have positive sputum smear results at the end of
the intensive phase of treatment and/or at 2 months into the
continuation phase of treatment. At the time of the survey,
there was no capacity to treat drug-resistant cases of TB using
DOTS-Plus for MDR TB in either region. For this reason,
patients were placed on standard DOTS regimens (category I
or II) in accordance with their prior TB treatment history,
irrespective of drug resistance results. New patients who had
not previously received treatment for TB for 1 month were
given a category I regimen consisting of daily doses of isoniazid,
rifampicin, pyrazinamide, and ethambutol, with or without
streptomycin for 2 months, followed by isoniazid and rifam-
picin 3 times weekly for 4 months. The category II regimen
for patients previously treated for TB for 1 month consisted
of receipt of all 5 drugs daily for 3 months minus streptomycin
for the last month, followed by isoniazid, rifampicin, and
ethambutol 3 times weekly for 5 months. Patients were hos-
pitalized during the intensive phase of treatment and received
doses during the continuation phase that were ostensibly ad-
ministered under direct observation by local health care work-
ers. Although information on adherence to treatment (doses
observed, doses given without observation, and missed doses)
was routinely recorded, the data were not considered to be
accurate enough to use for analysis.
Laboratory testing and statistical analysis. Because there
were no facilities for culture of sputum samples available in
either region or country at the time of the survey, sputum
samples were transported directly from both Karakalpakstan
and Dashoguz to the Supranational Reference Laboratory in
Borstel, Germany. Primary isolation and culture of mycobac-
terial isolates were performed as described elsewhere [13]. All
strains were tested for susceptibility to the 5 ﬁrst-line drugs
used in the DOTS program on Lo ¨wenstein-Jensen media,using
the proportion method. If there was insufﬁcient growth, drug
susceptibility was tested using the modiﬁed proportionmethod
in Bactec 460TB (Becton Dickinson Microbiology Systems).
Extraction of genomic DNA from mycobacterial strains and
DNA ﬁngerprinting using IS6110 as a probe were performed
according to a standardized protocol [14]. In addition, all iso-
lates were analyzed by the spoligotyping technique [15]. Mo-
lecular typing data were analyzed with Bionumerics software
(Windows NT, version 3.5; Applied Maths). The spoligotyping
data were used to additionally conﬁrm strain relationships and
to identify Beijinggenotypeisolates(nohybridizationtospacers
1–34, but hybridization to spacers 35–43). EpiInfo software,
version 6.04d (Centers for Disease Control and Prevention),
was used to calculate 95% CIs for proportions by Fisher’s exact
test and to compare proportions by x
2 test.
RESULTS
Study population and additional testing. In total, 416 pa-
tients were included in the original drug resistance survey (213
patients were from Karakalpakstan, and 203 patients were from
Dashoguz). Of these patients, 397 had strain cultures available
for IS6110 DNA ﬁngerprinting and spoligotyping analysis
(DNA testing). The 19 strains from the remaining patients did
not grow at the time of DNA testing. Of these 397 strains, 382
demonstrated clear-cut IS6110 banding patterns, and 15
showed mixed banding patterns, demonstrating double infec-
tion with 2 Mycobacterium tuberculosis strains. The 382 patients
with identiﬁable isolates form the population for this study.
These 382 patients were not different from the full sample
included in the drug resistance survey with regard to age, sex,
district of residence, or outcome of DOTS. The numbers of
new and previously treated patients, by regionandbycategories
of drug resistance and success of DOTS, are shown in table 1.
For analysis of ampliﬁcation of resistance, the 2 regions were
combined according to similar treatment outcomes, given the
same level of drug resistance and because of the small number
of patients in each resistance category. Overall, additional spu-Acquired Drug Resistance in TB • CID 2007:44 (1 June) • 1423
Table 1. Drug resistance and success of the short-course directly observed treatment (DOTS) regimen
among new and previously treated patients with tuberculosis in Karakalpastan, Uzbekistan, and Dashoguz,
Turkmenistan.
Drug resistance category
Karakalpakstan
(n p 198)
Dashoguz
(n p 184)
New patient
(n p 109)
Previously treated
patient
(n p 89)
New patient
(n p 100)
Previously treated
patient
(n p 84)
Pansusceptible 52 (79) 21 (62) 71 (82) 33 (67)
Monoresistant 20 (80) 14 (59) 20 (100) 18 (61)
Polyresistant 20 (55) 21 (67) 5 (100) 19 (58)
MDR
a 17 (24) 33 (24) 4 (50) 14 (21)
NOTE. Data are no. of patients (% of patients experiencing success of DOTS regimen). MDR, multidrug resistant.
a Resistant to at least isoniazid and rifampicin.
tum samples were obtained from 82 patients during treatment.
Of these patients, 62 were found to be infected with the same
strain of M. tuberculosis as that identiﬁed at diagnosis on the
basis of identical DNA ﬁngerprinting of the second samples.
The remaining 20 patients were excluded on the basis of a
different strain found atretesting(10patients),doubleinfection
at retesting (5 patients), and possible laboratorycontamination
(5 patients). Of the 62 patients, 34 had paired identical isolates
at diagnosis and at the end of the intensive phase of treatment,
and 14 had paired identical isolatesatdiagnosisandat2months
into the continuation phase of treatment. The remaining 14
patients were found to have identical isolates at both the end
of the intensive phase and at 2 months into the continuation
phase.
Ampliﬁcation of drug resistance. The drug resistance pro-
ﬁles of the 382 patients at diagnosis revealed high levels of
preexisting drug resistance; 150% of patients were infectedwith
a strain showing some level of drug resistance, and approxi-
mately one-third were infected with strains resistantto2ﬁrst-
line drugs (table 2). Overall, 19 (31%) of the 62 strains from
patients infected with identical strains at second testing devel-
oped new or additional drug resistance during treatment (table
2). All but 2 of these patients were infected with initially drug-
resistant strains at diagnosis. In addition to the 2 instances of
the development of drug resistance by initially pansusceptible
strains, 1 strain that was monoresistant at diagnosis acquired
additional drug resistance, giving an overall rate of ampliﬁca-
tion of 1.2% (95% CI, 0.3%–3.5%) for these groups. In con-
trast, 17% of strains with preexisting resistance to 11 drug but
not isoniazid and rifampicin, deﬁned here as polydrug resis-
tance, ampliﬁed their resistance during short-course chemo-
therapy (table 2). All except 1 of these strains developed ad-
ditional rifampicin resistance to become MDR. Signiﬁcant
ampliﬁcation was also found among the strains found to be
MDR at diagnosis, with 7% (95% CI, 2%–16%) developing
additional ﬁrst-line resistance (table 2).
Drug resistance at diagnosis and resistance ampliﬁed during
treatment are shown in table 3. Nineteen patients had strains
that ampliﬁed their resistance; 11 strains became MDR during
DOTS, and 12 developed either isoniazid or rifampicin resis-
tance. Overall, MDR TB strains developed during treatment in
11 of 314 patients who were not already infected with MDR
TB strains at diagnosis (3.5%; 95% CI, 1.8%–6.2%). Among
the strains that were already MDR, pyrazinamide was the most
common drug to which strains developed additionalresistance.
Most of the measured ampliﬁcation of resistance occurreddur-
ing the intensive phase of treatment, when patients were taking
the maximum number of drugs and were hospitalized. Ten of
the 19 patients were new patients and were therefore under-
going category I DOTS.
A striking observation was that resistance to both isoniazid
and streptomycin at diagnosis posed a signiﬁcant ampliﬁcation
risk, with 5 (12%) of 41 patients developing MDR TB strains
during treatment. This was not the case among the 21 patients
with isoniazid-monoresistant strains (table 2). An additional
interesting ﬁnding was that all 5 isoniazid- and streptomycin-
resistant TB strains that ampliﬁed their resistance were found
to be of the Beijing genotype. Among all polyresistant strains,
11 (39%) of 28 polyresistant Beijing genotype strains ampliﬁed
their resistance, compared with none of the 27 non-Beijing
polyresistant strains ( ). P ! .05
Among the 19 patients with strains that ampliﬁed their re-
sistance, treatment failure was the most common outcome of
DOTS treatment (in 13 patients). Of the remaining patients, 3
died during treatment, 1 defaulted (while continuing to have
positive sputum smear test results), and 2 were recorded as
being successfully treated after the intensive phase of treatment
was extended. However, 1 of the successfully treated patients
subsequently developed disease that was diagnosedbyapositive
sputum smear test result.
Changes from resistant to susceptible. There were some
instances of strains that were initially resistant becoming sus-1424 • CID 2007:44 (1 June) • Cox et al.
Table 2. Number of strains at diagnosis, at retesting, and demonstrating ampliﬁcation of resistance during treat-
ment, by drug resistance categories at diagnosis.
First-line drug resistance proﬁle at diagnosis
No. of
strains
at diagnosis
No. (%) of
identical strains
at retesting
a
Ampliﬁcation
detected among
identical strains,
no. of strains
(% of strains at
diagnosis; 95% CI)
Pansusceptible 177 12 (7) 2 (1.1; 0.1–4.0)
Monoresistant
All 72 10 (14) 1 (1.4; 0.0–7.5)
Isoniazid 21 1 (5) 0
Rifampicin 1 0 0
Ethambutol 0 0 0
Streptomycin 49 9 (18) 1 (2)
Pyrazinamide 1 0 0
Polyresistant
All 65 16 (25) 11 (17; 9–28)
Isoniazid, streptomycin 41 9 (22) 5 (12)
Isoniazid, pyrazinamide 3 0 0
Isoniazid, ethambutol 1 0 0
Isoniazid, ethambutol, streptomycin 12 4 (33) 3 (25)
Isoniazid, streptomycin, pyrazinamide 6 2 (33) 2 (33)
Isoniazid, ethambutol, streptomycin, pyrazinamide 2 1 (50) 1 (50)
MDR
b
All 68 24 (35) 5 (7; 2–16)
Isoniazid, rifampicin 1 1 (100) 1 (100)
Isoniazid, rifampicin, streptomycin 19 5 (26) 2 (11)
Isoniazid, rifampicin, streptomycin, pyrazinamide 3 2 (67) 0
Isoniazid, rifampicin, ethambutol, streptomycin 30 12 (40) 2 (7)
Isoniazid, rifampicin, ethambutol, streptomycin, pyrazinamide 15 4 (27) 0
Overall 382 62 (16) 19 (5; 3–8 )
NOTE. MDR, multidrug resistant.
a Only patients who had positive sputum smear results for tuberculosis during treatment were retested for drug resistance.
b Resistant to at least isoniazid and rifampicin.
ceptible to drugs. Five strains lost resistance to ethambutol and
3 strains lost resistance to streptomycin over the course of
treatment. All of the strains initially measured as ethambutol
resistant and later as ethambutol susceptible were also resistant
to several other drugs.
DISCUSSION
Our study, conducted in an area with high levels of drug re-
sistance, demonstrates the high levels of ampliﬁcation of drug
resistance that occur when patients are treated with standard
ﬁrst-line regimens in a DOTS program. Patients infected with
polyresistant TB strains are at risk of developing MDR TBwhen
treated with standard short-course chemotherapy.Overall,17%
of TB strains from these patientsampliﬁedtheirdrugresistance,
whereas 7% of strains that were already MDR also developed
additional ﬁrst-line drug resistance. In total, 3.5% of patients
not initially infected with MDR TB strains were found to have
developed MDR strains during treatment. The majority of pa-
tients whose strains demonstrated ampliﬁcation of resistance
also experienced poor outcomes of treatment, with treatment
failure or death predominating.
Our knowledge about the performance of standardized
DOTS in areas with high levels of drug resistance and the
potential impact of DOTS on ampliﬁcation of resistance is
limited. A large study performed in the Tomsk region of Russia,
where ∼20% of all patients with TB have MDR TB strains [1],
revealed results similar to those presented here. In Tomsk, fail-
ure of a DOTS category I treatment regimen was strongly as-
sociated with developing drug resistance. Acquired MDR TB
was demonstrated in 55% of patients who were not initially
infected with MDR strains and who experienced treatmentfail-
ure [12]. Similar to our study, the highest rate of ampliﬁcation
of resistance was recorded among patients with preexistingiso-
niazid or rifampicin resistance but not both; among this group,Acquired Drug Resistance in TB • CID 2007:44 (1 June) • 1425
Table 3. Ampliﬁcation of drug resistance during treatment and treatment outcomes for 19 patients with tuberculosis in whom
ampliﬁcation was detected.
Treatment category, patient
Beijing
genotype
Drug resistance
at diagnosis
Resistance
at end of
intensive phase
Resistance
2 months into
continuation phase
Treatment
outcome
Drug resistance
ampliﬁed
during treatment
Previously untreated patient
a
1 No Susceptible S S Failure S
2 Yes H, S … H, R, S Failure R
3 Yes H, S … H, R, S Failure R
4 Yes H, S H, R, S H, R, S Failure R
5 Yes H, S H, R, S … Default R
6 Yes H, E, S H, R, E, S H, R, S Failure R
7 Yes H, S, Z H, E, S, Z … Completion E
8 Yes H, R, S H, R, E, S, Z … Failure E, Z
9 Yes H, R, S H, R, S, Z … Death Z
10 Yes H, R, E, S H, R, E, S, Z … Cure Z
Previously treated patient
b
11 No Susceptible Susceptible H, R, S Failure H, R, S
12 No S H, S … Failure H
13 Yes H, S H, R, E, S … Failure R, E
14 Yes H, S, Z H, R, E, S, Z … Death R, E
1 5 Y e s H ,E ,S H ,R ,E ,S H ,R ,E ,S F a i l u r e R
16 Yes H, E, S H, R, E, S, Z … Failure R, Z
1 7 Y e s H ,E ,S ,Z H ,E ,S ,Z H ,R ,S ,Z F a i l u r e R
18 No H, R … H, R, E, S Failure E, S
19 Yes H, R, E, S H, R, E, S, Z H, R, Z, S Death Z
NOTE. Susceptible is deﬁned as pansusceptible to all 5 ﬁrst-line drugs tested. E, ethambutol; H, isoniazid; R, rifampicin; S, streptomycin; Z, pyrazinamide.
a New patients (previously untreated) received the following category I regimen: daily H, R, Z, and E, with or without S for 2 months, followed by H and
R 3 times weekly for 4 months.
b Patients previously treated received the following category II regimen: H, R, Z, E, and S daily for 3 months minus S for the last month, followed by H,
R ,a n dE3t i m e sweekly for 5 months.
71% developed MDR TB strains. Alarmingly, 18 of 31 patients
experiencing treatment failure in Tomsk whowereinfectedwith
drug-susceptible or streptomycin-monoresistant TB strains at
diagnosis also developed drug-resistant TB, most often MDR
TB.
However, the Tomsk study [12] did not include molecular
typing (DNA ﬁngerprinting) of additional culture specimens
obtained from patients showing the development of resistant
TB strains and, thus, could not distinguish between the various
reasons for changes in drug resistanceproﬁlesduringtreatment,
such as ampliﬁcation of resistance,mixedinfectionatdiagnosis,
or reinfection with a second strain. It has been demonstrated
that a signiﬁcant proportion of patients can be infected with
multiple strains of M. tuberculosis [16–18]. Given this scenario,
a previously undetected drug-resistant strain might emerge un-
der the pressure of chemotherapy as drug-susceptible strains
are killed. Multiple infections may also arise through the su-
perinfection of patients receiving treatment [19]. Furthermore,
it has been demonstrated that exogenous reinfection with a
second resistant or even MDR TB strain can be a signiﬁcant
cause of treatment failure and of the emergence of resistance
[20–22]. Finally, without DNA ﬁngerprinting, laboratory con-
tamination cannot be ruled out [23].
In contrast, our study included molecular genotyping of
strains obtained from a second set of samples, which allowed
likely reinfections, double infections, and potential laboratory
contaminations to be excluded. Only 3 instances of the ac-
quisition of drug resistance among initially pansusceptible or
monoresistant strains were found in this study (1.2% of this
group). In 1 of these cases, isoniazid, rifampicin, and strep-
tomycin resistance developed during the ambulatory, contin-
uation phase of treatment, when drug taking is not as well
supervised as it is during the hospitalized, intensive phase. The
development of streptomycin resistance may well be a result
of the practice of continuing streptomycin treatment privately
during DOTS on the basis of the common view that injections
are better than tablets [24]. Poor adherence can lead to drug
resistance in initially drug-susceptible strains because of inter-
mittent periods of not taking drugs or because of selectively
taking some drugs [8]. The relatively low level of acquisition
of drug resistance among pansusceptible or monoresistant
strains is reassuring and suggests that poor adherence is not a1426 • CID 2007:44 (1 June) • Cox et al.
signiﬁcant factor in the creation of drug resistance in the DOTS
program.
The highest rate of ampliﬁcation of resistance was observed
among isoniazid- and streptomycin-resistant isolates, whereas
none of the isoniazid-monoresistant strains developed further
resistance. This is somewhat surprising, considering that 3
drugs (rifampicin, pyrazinamide, and ethambutol) in the stan-
dard regimen would be expected to be active both for patients
with combined isoniazid and streptomycin resistance and for
those with isoniazid monoresistance. However, our data are in
accordance with the results of a study performed in Vietnam,
in which combined resistance to isoniazid and streptomycin
was found to be a strong risk factor for treatment failure and
relapse of TB and for acquired multidrug resistance among
patients experiencing treatment failure and relapse of TB [10].
The availability of mycobacterial genotyping data also al-
lowed us to investigate the association between infection with
Beijing genotype strains and ampliﬁcation of resistance. Al-
though the number of patients was small, ampliﬁcation of re-
sistance appeared to be more common among strains of the
Beijing genotype; nearly one-third of polyresistant Beijing
strains ampliﬁed their resistance during standard DOTS che-
motherapy, whereas none of the non-Beijing strains with a
similar resistance proﬁle did so.
These data indicate that, in cases of preexisting polyresist-
ance, Beijing genotype strains have a higher capacity to develop
further drug resistance than do strains of other M. tuberculosis
complex genotypes. Such a capacity might then result in a
selective advantage for Beijing genotype strains in regions with
high levels of drug resistance. This is in accordance with and
might bethereason for thehighratesofBeijinggenotypestrains
found in several regions of the former Soviet Union and for
the observed association with MDR TB [25–27]. The mecha-
nism potentially allowing Beijing genotype strains to develop
resistance more readily is not known. Our results indicate that,
especially for Beijing genotypestrains,alternativetreatmentreg-
imens might be required to avoid ampliﬁcation of resistance
and development of MDR TB. Therefore, further research is
urgently needed to determine the implications of these ﬁndings
for treatment of individual patients in areas with high levels of
drug resistance.
The levels of ampliﬁcation of drug resistance found in our
study are likely to be a signiﬁcant underestimate of the true
situation. Only patients who had positive sputum smear results
during treatment were retested for drug resistance. Because
sputum smear microscopy is relatively insensitive, particularly
during treatment, it is possible that more patients could have
remained culture-positive for TB throughout treatment [28].
Had sputum samples from all patients beencultured,additional
resistance ampliﬁcation might have been detected. Indeed,
many of the patients infected with drug-resistant strains of TB
at diagnosis who were classiﬁed as successfully treated with
DOTS were subsequently found to havesmear-positiveTB[29].
There is a range of possible explanations for the changes in
drug resistance from resistant to susceptible that were observed
in some cases in our study. First, proﬁciency testing suggests
that drug susceptibility testing is less accurate for ethambutol
and streptomycin than it is for rifampicin and isoniazid [30].
Drug susceptibility testing in our study was conducted by the
National Reference Centre for Mycobacteria in Germany, a
member of the Supranational Reference Laboratory Network
established in 1994 [31]. As a member of the Supranational
Reference Laboratory Network, our laboratory participates in
a quality assurance and proﬁciency testing program. Testingfor
susceptibility to ethambutol is often problematic; there is a
small difference between the critical concentration used for
drug susceptibility testing and the MIC, which may explain the
discordant results [32, 33]. For streptomycin, similarly discor-
dant results may be explained by observations from some of
the early trials of streptomycin treatment in which reversion
of streptomycin resistance to susceptibility was shown to occur
[34]. Finally, it has previously been demonstrated that bacillary
populations from the same patient can display different resis-
tance proﬁles [35–37]. Different resistance proﬁles in sputum
samples obtained throughout treatment may, therefore, rep-
resent different bacillary populations in different parts of the
lung.
In conclusion, our study demonstrated a high risk of am-
pliﬁcation of drug resistance among patients treatedusingstan-
dard DOTS regimens. These results indicate that, in areas with
high levels of drug resistance in which 140% of all smear-
positive patients are infected with strains of TB with initial
ﬁrst-line drug resistance, systematic drug susceptibility testing,
followed by appropriate treatment for drug-resistant TB, is re-
quired to identify those at high risk for both treatment failure
and ampliﬁcation of drug resistance and, therefore, subsequent
death. The additional laboratory costs associated with culture
and drug susceptibility testing need to be weighed against the
cost of treating newly created additional cases of MDR TB with
lengthy second-line drug regimens. Additional work is required
to determine the level of drug resistance among patients with
TB (both new and previously treated) at which routine drug
susceptibility testing should be used to avoid the creation of
unnecessary and costly drug resistance.
Furthermore, our data indicate that strains of the Beijing
genotype with preexisting resistance have a higher risk of de-
veloping additional resistance during standard treatment. This
has potentially serious consequencesforthediagnosisandtreat-
ment of TB and suggests that further longitudinal studies in
areas with a high incidence of TB are required to investigate
this phenomenon and conﬁrm our ﬁndings.Acquired Drug Resistance in TB • CID 2007:44 (1 June) • 1427
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